NCT02744612View on ClinicalTrials.gov

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 20, 2016

Primary Completion Date

March 3, 2021

Study Completion Date

July 30, 2024

Conditions
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

DRUG

Ibrutinib

Given PO

Trial Locations (3)

10065

NYP/Weill Cornell Medical Center, New York

43210

Ohio State University Comprehensive Cancer Center, Columbus

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02744612 - Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter